Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies
New York, New York--(Newsfile Corp. - November 21, 2022) - PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world's biggest public health crises.Lexaria BioscienceTo view an enhanced version of this graphic, please visit:
2022-11-21 9:19 AM EST
Soligenix Enters Q4 With Multiple Catalysts in Play
New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational year in 2023.Following its successful Phase 3 clinical trial evaluating HyBryte (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL), Soligenix is preparing to file a New Drug Application (NDA) with the FDA. HyBryte™ will potentially be a first-in-class...
2022-10-13 8:30 AM EDT
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' Results
New York, New York--(Newsfile Corp. - September 20, 2022) - PCG Digital - Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain.There is currently only one FDA approved CBD drug available on the market,...
2022-09-20 8:30 AM EDT
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL
New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryte™ therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare...
2022-09-12 8:30 AM EDT
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses.
2022-08-08 8:30 AM EDT
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the largest placebo controlled, randomized Phase 3 trial ever done in cutaneous T-cell lymphoma (CTCL) evaluating a novel topical treatment for early-stage CTCL and is preparing to submit a New Drug Application to the FDA to commercialize the product.
2022-07-26 9:27 AM EDT
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASDAQ: VIRI) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection. VIRI is anticipating top line results this September from its ongoing FM Phase 2b trial, featuring its lead combination...
2022-07-26 8:30 AM EDT
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NASDAQ: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in September. Virios TherapeuticsTo view an enhanced version of this graphic, please
2022-07-19 8:30 AM EDT
The Ascension of Asensus in Performance-Guided Surgery
New York, New York--(Newsfile Corp. - June 28, 2022) - PCG Digital -- In a recent interview, Shameze Rampertab, CFO of Asensus Surgical (NYSE American: ASXC), shared more of the Performance-Guided Surgery™ company's 2022 plans and progress.Surgery ReimaginedTo view an enhanced version of this graphic, please v
2022-06-28 8:30 AM EDT
Quoin Pharmaceuticals: Strategically Building For Future Success
New York, New York--(Newsfile Corp. - June 14, 2022) - PCG Digital -- The life sciences industry has always been dynamic; a collective of organizations from small and agile to large multinationals with one common feature, a need to be creative enough to adapt and change course as challenges arise. Social, political and economic influences, the regulatory environment and competition from deep-pocketed Big Pharma all present substantial challenges for small biotech companies. The overarching...
2022-06-14 8:30 AM EDT
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
New York, New York--(Newsfile Corp. - June 7, 2022) - PCG Digital -- Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and commercializing products to treat rare diseases where there is an unmet medical need. (Rising to the challenges of rare disease treatment)
2022-06-07 8:30 AM EDT
BIONIK Laboratories: Strong Sales Pipeline Delivering Hope to Stroke Survivors
New York, New York--(Newsfile Corp. - May 25, 2022) - PCG Digital - Stroke is an enormous public health issue that can strike anyone at any time, regardless of age or health status. Worldwide, stroke is the second leading cause of death and a leading cause of serious long-term disability. According to the American Heart Association, each year stroke affects 800,000 individuals. More than two thirds of stroke survivors receive rehabilitation services after hospitalization.
2022-05-25 10:45 AM EDT
Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome
New York, New York--(Newsfile Corp. - May 17, 2022) - PCG Digital -- People with rare diseases face severe limitations, debilitating discomfort, and a very uncertain future. Children are especially vulnerable: 3 out of 10 children born with a rare disease do not live to see their 5th birthday. Rare diseases can be challenging to diagnose, but even once a diagnosis is reached, effective treatment options can be even more elusive.
2022-05-17 8:30 AM EDT
Snacks Sabotaging Your Sleep? Nightfood Establishes Nighttime Snacking Category
New York, New York--(Newsfile Corp. - May 11, 2022) - PCG Digital -- Anyone who has spent a night tossing and turning after eating the wrong thing before bed will tell you: What you eat before bed matters. Nighttime snacking company, Nightfood Holdings, Inc., (OTCQB: NGTF) is not only defining the problem of snacking between dinner and bedtime - which sees Americans spending $50 billion each year on evening snacks - but developing sleep-friendly solutions.The company's sleep-friendly snacking...
2022-05-11 12:09 PM EDT
Investing in 60 Seconds: Asensus Surgical
New York, New York--(Newsfile Corp. - April 20, 2022) - PCG Digital -- Surgery can be unpredictable, and a staggering one in five patients undergoing surgery has one, or even multiple, preventable surgical complications.Asensus Surgical (NYSE American: ASXC) is setting a new standard for robotic, laparoscopic surgery with its technology platform, Senhance®, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence (AI) and machine learning (ML). The Senhance...
2022-04-20 8:30 AM EDT
Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024
New York, New York--(Newsfile Corp. - March 24, 2022) - PCG Digital -- Netherton Syndrome (NS) is a rare and devastating skin disease that is estimated to affect between 2,000 and 4,000 people in the United States, and a similar number in Europe. It has no cure, and current treatment primarily involves the use of over-the-counter moisturizers which provide only minor symptomatic relief.Quoin Pharmaceuticals' (NASDAQ: QNRX) investigational product for NS, QRX003, may become the first approved...
2022-03-24 8:30 AM EDT
Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy
New York, New York--(Newsfile Corp. - February 8, 2022) - PCG Digital - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase 'Rare diseases are only rare if you don't live with one' to emphasize its own mission: to deliver unique solutions to help treat rare disorders that have no approved treatments or cures.
2022-02-08 8:30 AM EST
Asensus Surgical: Reimagining the Future of Surgery
New York, New York--(Newsfile Corp. - January 26, 2022) - -- PCG Digital-- Asensus Surgical, Inc. (NYSE American: ASXC) is leading the digital surgical market with a new concept known as Performance-Guided Surgery™. Asensus SurgicalTo view an enhanced version of this graphic, please visit:
2022-01-26 1:10 PM EST
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)
New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutical ingredient for SGX301, aka HyBryte™, the company is still on track to file a new drug application with the FDA in the latter half of 2022. HyBryte™ is an early-stage treatment for cutaneous T-cell...
2022-01-12 12:00 PM EST
The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics
New York, New York--(Newsfile Corp. - December 14, 2021) - PCG Digital -- Drug development is complex, lengthy and expensive, and not without its risks. Bringing a drug to market takes years, with costs quickly running into hundreds of millions of dollars, and no promise of success at the end of it all. Rare and orphan indications provide an R&D 'sweet spot' for biopharmaceutical companies pursuing drug development. Drugs for rare diseases have a high rate of success in obtaining...
2021-12-14 8:30 AM EST